IE
QNCX icon

Israel Englander’s Quince Therapeutics QNCX Stock Holding History

Israel Englander’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-450
Closed -$1.14M – 7377
2021
Q4 		$1.14M Buy
450
+420
+1,400% +$2.56M ﹤0.01% 4294
2021
Q3 		$550K Buy
+30
New +$477K ﹤0.01% 5260

Other funds holding QNCX

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Israel Englander's QNCX Position: Q2 2026 in Review

Israel Englander increased its Quince Therapeutics (QNCX) stake by 465% in Q2 2026, buying an estimated $1.34M and bringing the position to 70,779 shares worth $1.29M. The position accounts for ﹤0.01% of the portfolio, ranked #4151.

Israel Englander first reported a position in QNCX in Q2 2019 and has held it in 23 quarters since. The position peaked at $7.15M in Q4 2021. 27 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

  • Israel Englander held 70,779 shares of Quince Therapeutics worth $1.29M as of Q2 2026.
  • Israel Englander bought 58,260 Quince Therapeutics shares in Q2 2026, an estimated $1.34M.
  • Quince Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #4151 holding.
  • Israel Englander first reported a position in Quince Therapeutics in Q2 2019 and has held it in 23 quarters since.
  • Israel Englander's Quince Therapeutics position peaked at $7.15M in Q4 2021.
  • 27 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.